联环药业：产品“法莫替丁注射液”取得注册证

Group 1 - The core point of the article is that Lianhuan Pharmaceutical has received approval from the National Medical Products Administration for its product "Famotidine Injection" [1] - Lianhuan Pharmaceutical's revenue composition for the year 2024 is as follows: 59.36% from pharmaceutical distribution, 40.38% from pharmaceutical manufacturing, and 0.26% from other businesses [1] - The current market capitalization of Lianhuan Pharmaceutical is 6 billion yuan [2]